NASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Price, News & Analysis $216.58 -4.17 (-1.89%) Closing price 04:00 PM EasternExtended Trading$216.50 -0.08 (-0.04%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Axsome Therapeutics Stock (NASDAQ:AXSM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Axsome Therapeutics alerts:Sign Up Key Stats Today's Range$216.00▼$223.2950-Day Range$198.52▼$249.7652-Week Range$112.90▼$260.19Volume718,760 shsAverage Volume535,585 shsMarket Capitalization$11.34 billionP/E RatioN/ADividend YieldN/APrice Target$267.60Consensus RatingModerate Buy Company Overview Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. The company’s research programs address conditions with substantial unmet medical needs, including depression, migraine, narcolepsy, excessive daytime sleepiness, agitation associated with Alzheimer’s disease, and other neurological or psychiatric disorders. Axsome’s commercial portfolio includes Auvelity, an oral medicine approved in the United States for the treatment of major depressive disorder in adults. The company also markets Sunosi (solriamfetol) in the United States for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Axsome obtained rights to Sunosi from Jazz Pharmaceuticals. The company is advancing additional product candidates, including therapies being evaluated for Alzheimer’s disease agitation, migraine, narcolepsy, and other CNS conditions. Axsome was founded in 2012 and is headquartered in New York. Its founder and chief executive officer is Herriot Tabuteau, M.D.AI Generated. May Contain Errors. Read More Axsome Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreAXSM MarketRank™: Axsome Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 221st out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingAxsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 17 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAxsome Therapeutics has a consensus price target of $267.60, representing about 23.6% upside from its current price of $216.58.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Axsome Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($2.80) to $4.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -57.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -57.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 123.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Axsome Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.41% of the float of Axsome Therapeutics has been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 5.83.Change versus previous monthShort interest in Axsome Therapeutics has recently decreased by 3.91%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.74 News SentimentAxsome Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Axsome Therapeutics this week, compared to 9 articles on an average week.Search Interest17 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 143% compared to the previous 30 days.MarketBeat Follows10 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,557,062.00 in company stock.Percentage Held by Insiders20.60% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Axsome Therapeutics' insider trading history. Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AXSM Stock News HeadlinesAxsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14 at 5:00 PM | seekingalpha.comAXSM jumps 6% as Mizuho calls Auvelity’s Alzheimer’s launch a ‘strong start’September 11 at 7:06 PM | msn.comGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet production stayed at 5.9 million ounces, unchanged from 2020. Newmont, Barrick and Agnico all face the same reserve shortage, pushing majors toward acquiring smaller producing miners. Recent deals show the pattern: Rupert Resources jumped 67 percent and G2 Goldfields jumped 79 percent the day their buyouts were announced. Analyst Garrett Goggin has identified four junior miners he believes are next on the shopping list.September 14 at 1:00 AM | Golden Portfolio (Ad)Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeptember 10, 2026 | seekingalpha.comAxsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?September 10, 2026 | fool.comAxsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeptember 9, 2026 | seekingalpha.comAxsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?September 9, 2026 | finance.yahoo.comMark Jacobson Sells 10,000 Shares of Axsome Therapeutics (NASDAQ:AXSM) StockSeptember 4, 2026 | insidertrades.comSee More Headlines AXSM Stock Analysis - Frequently Asked Questions How have AXSM shares performed this year? Axsome Therapeutics' stock was trading at $182.64 at the beginning of 2026. Since then, AXSM stock has increased by 18.6% and is now trading at $216.58. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its quarterly earnings results on Monday, August, 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by $0.10. The business had revenue of $218.38 million for the quarter, compared to analyst estimates of $221.11 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 265.55% and a negative net margin of 24.68%. Read the conference call transcript. When did Axsome Therapeutics IPO? Axsome Therapeutics (AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' top institutional investors include California State Teachers Retirement System (21.34%), BlackRock Inc. (6.03%), Wellington Management Group LLP (1.25%) and Assenagon Asset Management S.A. (0.88%). Insiders that own company stock include Roger Jeffs, Nick Pizzie, Mark Coleman, Mark E Saad, Mark L Jacobson, Ari Maizel, Herriot Tabuteau and Hunter R Murdock. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Axsome Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Company Calendar Last Earnings8/10/2026Today9/14/2026Morgan Stanley 24th Annual Global Healthcare Conference9/14/2026H.C. Wainwright 28th Annual Global Investment Conference9/16/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 12 days, AXSM's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AXSM CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees925Year Founded2012Price Target and Rating Average Price Target for Axsome Therapeutics$267.60 High Price Target$380.00 Low Price Target$179.00 Potential Upside/Downside+23.6%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($3.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$183.17 million Net Margins-24.68% Pretax Margin-24.61% Return on Equity-265.55% Return on Assets-28.10% Debt Debt-to-Equity Ratio1.52 Current Ratio1.43 Quick Ratio1.34 Sales & Book Value Annual Sales$638.50 million Price / Sales17.77 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book123.76Miscellaneous Outstanding Shares52,380,000Free Float41,591,000Market Cap$11.34 billion OptionableOptionable Beta0.71 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:AXSM) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredGold just passed our debt as the world's #1 assetChina's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredA new American Civil War is coming?Whitney Tilson, the analyst CNBC once dubbed The Prophet, is warning that a new kind of national divide could ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
